JP5097135B2 - B型肝炎ワクチンの免疫応答を促進するタンパク質およびその遺伝子 - Google Patents
B型肝炎ワクチンの免疫応答を促進するタンパク質およびその遺伝子 Download PDFInfo
- Publication number
- JP5097135B2 JP5097135B2 JP2008558624A JP2008558624A JP5097135B2 JP 5097135 B2 JP5097135 B2 JP 5097135B2 JP 2008558624 A JP2008558624 A JP 2008558624A JP 2008558624 A JP2008558624 A JP 2008558624A JP 5097135 B2 JP5097135 B2 JP 5097135B2
- Authority
- JP
- Japan
- Prior art keywords
- hepatitis
- vaccine
- protein
- gene
- immune response
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
B型肝炎表面抗原結合タンパク質をコードするcDNAクローンは、ヒト肝臓cDNAファージ発現ライブラリーを、イムノブロッティングにより、ヒトプラズマから精製した完全B型肝炎表面抗原(プレS1、プレS2、およびSゾーンを含む)でスクリーニングすることによって得られた。遺伝子配列決定の結果により、1035bpの独立したオープンリーディングフレーム(ORF)が解明された(配列表の配列番号1)。このcDNAでは、344個のアミノ酸残基がコードされ、理論上の分子量は、38kuであった。等電点(PI)は、8.0であった。推定配列により、典型的な膜貫通領域が示唆され、およびイムノグロブリンスーパーファミリーへの分類が示唆された。ORFによりコードされるタンパク質の配列は、配列表の配列番号2に示される通りである。
タンパク質の発現および精製は、上述の遺伝子が、原核または真核発現ベクター中でクローン化された後になされた。全遺伝子は、pBV220原核発現ベクター中にクローン化された。大腸菌に組換えベクターをトランスフェクトした。ポジティブモノクローンを、液体培養培地中で培養した。タンパク質発現は、最初に37℃にて、次に42℃にて、5時間誘導した。タンパク質を、Ni−NTAアガロースアフィニティーカラムで精製された。精製されたタンパク質は、透析によって、リネイチャーされた。タンパク質とターゲットとの相互作用は、ELISAおよびウエスタンブロッティングにて確認された。
血液を最初の免疫の20日後に尾静脈から得た。血清中のB型肝炎表面抗原に対する抗体のレベルは、ELISAによって決定した。SPSSソフトウエアをグループの相違を分析する為に用いた。
Claims (5)
- 配列表の配列番号2に記載のアミノ酸配列からなるタンパク質を含む、B型肝炎ワクチンのアジュバント。
- 前記アミノ酸配列が、配列表の配列番号1に記載のポリヌクレオチド配列でコードされる、請求項1記載のB型肝炎ワクチンのアジュバント。
- ワクチンと共に皮下投与される、請求項1または2に記載のB型肝炎ワクチンのアジュバント。
- B型肝炎ウィルス表面抗原を、配列表の配列番号2に記載のアミノ酸配列からなるタンパク質と組み合わせることによって、効力が強化されたB型肝炎ワクチンを得る方法。
- 前記アミノ酸配列が、配列表の配列番号1記載の核酸配列によってコードされる、請求項4記載の効力が強化されたB型肝炎ワクチンを得る方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100247565A CN100503827C (zh) | 2006-03-16 | 2006-03-16 | 一种乙型肝炎病毒疫苗增效蛋白及其基因 |
CN200610024756.5 | 2006-03-16 | ||
PCT/CN2007/000844 WO2007104263A1 (zh) | 2006-03-16 | 2007-03-16 | 一种乙型肝炎病毒疫苗增效蛋白及其基因 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009529334A JP2009529334A (ja) | 2009-08-20 |
JP5097135B2 true JP5097135B2 (ja) | 2012-12-12 |
Family
ID=38018117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008558624A Active JP5097135B2 (ja) | 2006-03-16 | 2007-03-16 | B型肝炎ワクチンの免疫応答を促進するタンパク質およびその遺伝子 |
Country Status (4)
Country | Link |
---|---|
US (1) | US8895237B2 (ja) |
JP (1) | JP5097135B2 (ja) |
CN (1) | CN100503827C (ja) |
WO (1) | WO2007104263A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106177932A (zh) * | 2016-07-03 | 2016-12-07 | 查文娟 | 一种耐甲氧西林金黄色葡萄球菌的疫苗 |
CN109294968B (zh) * | 2017-07-25 | 2022-06-14 | 格兰柏生化科技有限公司 | 一种动物核酸疫苗的大规模生产技术 |
CN114702573B (zh) * | 2022-02-28 | 2024-04-05 | 中国科学院生物物理研究所 | 乙肝病毒表面s蛋白高亲和力纳米抗体及其应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE602004028270D1 (de) * | 2003-11-04 | 2010-09-02 | Novartis Vaccines & Diagnostic | Verwendung von antagonisten-anti-cd40-antikörpern zur behandlung von chronisch lymphozytischer leukämie |
-
2006
- 2006-03-16 CN CNB2006100247565A patent/CN100503827C/zh not_active Expired - Fee Related
-
2007
- 2007-03-16 WO PCT/CN2007/000844 patent/WO2007104263A1/zh active Application Filing
- 2007-03-16 US US12/282,754 patent/US8895237B2/en active Active
- 2007-03-16 JP JP2008558624A patent/JP5097135B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
CN100503827C (zh) | 2009-06-24 |
WO2007104263A1 (zh) | 2007-09-20 |
WO2007104263A8 (zh) | 2009-07-30 |
JP2009529334A (ja) | 2009-08-20 |
US8895237B2 (en) | 2014-11-25 |
US20100055135A1 (en) | 2010-03-04 |
CN1948493A (zh) | 2007-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2023186170A1 (zh) | 一种新冠病毒Delta和Omicron变异株嵌合抗原、其制备方法和应用 | |
JP3825041B2 (ja) | 外来t−細胞エピトープを補助として用いた、自己タンパク質に対する抗体応答の誘発 | |
US9751914B2 (en) | Polypeptides and antibodies for treating HBV infection and related diseases | |
JP6613399B2 (ja) | Hbvに対する免疫応答を生じさせるために用いられるウイルス様粒子 | |
JP2002528393A5 (ja) | ||
JP2023531291A (ja) | 融合タンパク質ワクチンプラットフォームの構築と応用 | |
JP5097135B2 (ja) | B型肝炎ワクチンの免疫応答を促進するタンパク質およびその遺伝子 | |
CN115137812A (zh) | 融合蛋白疫苗平台的构建与应用 | |
US20160324954A1 (en) | Immunogenic compositions for inhibiting hepatitis d virus | |
CN1994465B (zh) | Ccr5自体多肽疫苗及其制备方法 | |
US6558675B1 (en) | Mutant human hepatitis B viral strain and uses thereof | |
US20040209292A1 (en) | Mutant human hepatitis B viral strain and uses thereof | |
JP2020506875A (ja) | B型肝炎ウイルス様粒子をアジュバントとして含むワクチン組成物 | |
CN110898219A (zh) | 基于铁蛋白与preS1抗原基因融合表达的疫苗 | |
DE69814884T2 (de) | Hepatitis b virale polypeptide | |
EP3912988A1 (en) | Three-dimensional epitope of hepatitis b surface antigen and antibody binding specifically thereto | |
CN112262153B (en) | Efficient antibody induction method, antibody and detection system for hepatitis virus | |
CN110407944B (zh) | 隐孢子虫多表位基因片段cpmcef及其融合蛋白和应用 | |
JPH01110699A (ja) | 神経細胞ポリペプチド及びその製造方法及び使用 | |
WO2024049946A1 (en) | Compositions targeting apoptosis-associated speck-like protein with caspase activation and recruitment domain (asc) and methods of use | |
CN112262153A (zh) | 高效的肝炎病毒的抗体诱导方法、抗体以及检测系统 | |
NZ528739A (en) | A mutant human hepatitis B viral strain and uses thereof | |
KR20190059652A (ko) | 일본 뇌염 바이러스 피막 단백질의 돌출 도메인을 포함하는 단백질, 이의 동형이량체, 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110825 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111124 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111201 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111222 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120418 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120816 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20120823 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120907 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120921 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5097135 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150928 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |